Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Rev Clin Pharmacol. 2011 May;4(3):329-34. doi: 10.1586/ecp.11.7.

Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review.

Author information

  • 1Department of Medicine, Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Leonard M Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL 33136, USA.

Abstract

The novel paclitaxel formulation (nanoparticle albumin-bound [nab] paclitaxel (Abraxane(®)) has recently been approved by the US FDA for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months after adjuvant chemotherapy. Apart from its superior efficacy, as demonstrated in the pivotal Phase III study, less toxicity compared with the traditional solvent-containing paclitaxel (Taxol(®)) seems to contribute to its favorable therapeutic index. While approved as a single agent, nab-paclitaxel may prove more effective in combination with either biologic agents and/or other cytotoxic chemotherapeutic agents, as summarized in this article.

PMID:
22114779
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk